The NeoALTTO clinical trial demonstrated that the combination of trastuzumab and lapatinib in the neoadjuvant setting exhibited a higher pathological complete response (pCR) in patients with HER2+ breast cancer, but overall survival and disease-free survival presented no significant differences [144,145,146]. Here, ERBB2 is linked to breast cancer.